Dosing has begun in a Phase 1 clinical trial testing Inhibikase Therapeutics’ investigational oral therapy IkT-148009 for Parkinson’s disease and related disorders in healthy volunteers. This first clinical trial (NCT04350177) is expected to enroll 112 healthy adults, ages 45 to 70, at a single site in…
People with low levels of lymphocytes, a type of white blood cell, may be at higher risk of Parkinson’s disease later in life, a large database study reports. While noting that low white blood cell counts may be a consequence of early Parkinson’s or of a yet unknown cause —…
Neupro patches (rotigotine) — a transdermal form of dopamine treatment — are known to help ease motor symptoms of Parkinson’s disease, and their use can also help with several its non-motor symptoms, researchers report. Their paper, “Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of…
The Sheffield Institute for Translational Neuroscience, known as SITraN, has joined with Verge Genomics to develop new therapeutic targets and screen the latest compounds for the treatment of neurodegenerative disorders such as Parkinson’s disease. The aim of this partnership is to accelerate the validation of new therapeutic candidates…
Researchers from Malmö University in Sweden are developing an interactive digital health tool, called Parkapp, to monitor symptoms and help diagnose Parkinson’s disease. The mobile app is able to monitor finger movements, voice samples and motion patterns as the conventional smartphone screen is tapped, making it possible to gather…
Cell therapy for Parkinson’s disease — especially that based on stem cells — holds great potential but come with significant challenges yet to be overcome. The International Parkinson and Movement Disorder Society (MDS) recently commissioned a report on the state of stem cell therapies in Parkinson’s, to both…
Insightec announced that its incision-free brain “surgery” technology — called Exablate 4000 (Exablate Neuro) — has been approved in China to treat essential tremor and tremors caused by Parkinson’s disease. The market approval from China’s regulatory agency for medicines and medical devices, the National Medical Products Administration, will allow the…
YTX-7739, a potential disease-modifying therapy for Parkinson’s disease, was safe, well-tolerated, and found to have a favorable pharmacological profile when given to a group of healthy volunteers. Yumanity Therapeutics provided those early findings from a recently completed single ascending-dose (SAD) Phase 1 clinical trial. Based on the results, Yumanity…
Alterity Therapeutics has been awarded a grant from the Michael J. Fox Foundation (MJFF) for animal studies to determine the optimal dose its of lead candidate ATH434, an essential step to opening trials in people with Parkinson’s disease. “I look forward to seeing the results from the…
To encourage more diversity in Parkinson’s investigations and better capture how the disorder affects patients across racial, socioeconomic, and other lines, The Michael J. Fox Foundation (MJFF) has opened an international program to fund projects that promote greater inclusion in Parkinson’s research. Awarded projects could receive from $50,000 up to…
Get regular updates to your inbox.
